TY - JOUR
T1 - Endogenous Circulating Sex Hormone Concentrations and Colon Cancer Risk in Postmenopausal Women
T2 - A Prospective Study and Meta-Analysis
AU - Mori, Nagisa
AU - Keski-Rahkonen, Pekka
AU - Gicquiau, Audrey
AU - Rinaldi, Sabina
AU - Dimou, Niki
AU - Harlid, Sophia
AU - Harbs, Justin
AU - Van Guelpen, Bethany
AU - Aune, Dagfinn
AU - Cross, Amanda J.
AU - Tsilidis, Konstantinos K.
AU - Severi, Gianluca
AU - Kvaskoff, Marina
AU - Fournier, Agnès
AU - Kaaks, Rudolf
AU - Fortner, Renee Turzanski
AU - Schulze, Matthias B.
AU - Jakszyn, Paula
AU - Sanchez, Maria Jose
AU - Colorado-Yohar, Sandra M.
AU - Ardanaz, Eva
AU - Travis, Ruth
AU - Watts, Eleanor L.
AU - Masala, Giovanna
AU - Krogh, Vittorio
AU - Tumino, Rosario
AU - Sacerdote, Carlotta
AU - Panico, Salvatore
AU - Bueno-De-Mesquita, Bas
AU - Gram, Inger Torhild
AU - Waaseth, Marit
AU - Gunter, Marc J.
AU - Murphy, Neil
N1 - Funding Information:
This work was supported by the French National Cancer Institute (INCa SHSESP17, grant No. 2017-127 to N. Murphy). The coordination of EPIC is financially supported by International Agency for Research on Cancer (IARC) and also by the Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, which has additional infrastructure support provided by the NIHR Imperial Biomedical Research Centre (BRC). The national cohorts are supported by: Danish Cancer Society (Denmark); Ligue Contre le Cancer, Institut Gustave Roussy, Mutuelle Gen erale de l’Education Nationale, Institut National de la Sante et de la Recherche Medicale (INSERM) (France); German Cancer Aid, German Cancer Research Center (DKFZ), German Institute of Human Nutrition Potsdam-Rehbruecke (DIfE), Federal Ministry of Education and Research (BMBF) (Germany); Associazione Italiana per la Ricerca sul Cancro-AIRC-Italy, Compagnia di SanPaolo and National Research Council (Italy); Dutch Ministry of Public Health, Welfare and Sports (VWS), Netherlands Cancer Registry (NKR), LK Research Funds, Dutch Prevention Funds, Dutch ZON (Zorg Onderzoek Nederland), World Cancer Research Fund (WCRF), Statistics Netherlands (the Netherlands); Health Research Fund (FIS) - Instituto de Salud Carlos III (ISCIII), Regional Governments of Andalucıa, Asturias, Basque Country, Murcia and Navarra, and the Catalan Institute of Oncology—ICO (Spain); Swedish Cancer Society, Swedish Research Council and County Councils of Skane and Vasterbotten € (Sweden); Cancer Research UK (14136 to EPIC-Norfolk; C8221/A29017 to EPIC-Oxford), Medical Research Council (1000143 to EPIC-Norfolk; MR/ M012190/1 to EPIC-Oxford) (United Kingdom).
Publisher Copyright:
© The Author(s) 2021. Published by Oxford University Press.
PY - 2021/12/1
Y1 - 2021/12/1
N2 - Background: Observational studies have consistently reported that postmenopausal hormone therapy use is associated with lower colon cancer risk, but epidemiologic studies examining the associations between circulating concentrations of endogenous estrogens and colorectal cancer have reported inconsistent results. Methods: We investigated the associations between circulating concentrations of estrone, estradiol, free estradiol, testosterone, free testosterone, androstenedione, dehydroepiandrosterone (DHEA), progesterone, and sex hormone–binding globulin (SHBG) with colon cancer risk in a nested case-control study of 1028 postmenopausal European women (512 colon cancer cases, 516 matched controls) who were noncurrent users of exogenous hormones at blood collection. Multivariable conditional logistic regression models were used to compute odds ratios and 95% confidence intervals to evaluate the association between circulating sex hormones and colon cancer risk. We also conducted a dose-response meta-analysis of prospective studies of circulating estrone and estradiol with colorectal, colon, and rectal cancer risk in postmenopausal women. All statistical tests were 2-sided. Results: In the multivariable model, a nonstatistically significantly positive relationship was found between circulating estrone and colon cancer risk (odds ratio per log2 1-unit increment ¼ 1.17 [95% confidence interval ¼ 1.00 to 1.38]; odds ratioquartile4-quartile1 ¼ 1.33 [95% confidence interval ¼ 0.89 to 1.97], Ptrend ¼ .20). Circulating concentrations of estradiol, free estradiol, testosterone, free testosterone, androstenedione, DHEA, progesterone, and SHBG were not associated with colon cancer risk. In the dose-response meta-analysis, no clear evidence of associations were found between circulating estradiol and estrone concentrations with colorectal, colon, and rectal cancer risk. Conclusion: Our observational and meta-analysis results do not support an association between circulating concentrations of endogenous sex hormones and colon or rectal cancer in postmenopausal women.
AB - Background: Observational studies have consistently reported that postmenopausal hormone therapy use is associated with lower colon cancer risk, but epidemiologic studies examining the associations between circulating concentrations of endogenous estrogens and colorectal cancer have reported inconsistent results. Methods: We investigated the associations between circulating concentrations of estrone, estradiol, free estradiol, testosterone, free testosterone, androstenedione, dehydroepiandrosterone (DHEA), progesterone, and sex hormone–binding globulin (SHBG) with colon cancer risk in a nested case-control study of 1028 postmenopausal European women (512 colon cancer cases, 516 matched controls) who were noncurrent users of exogenous hormones at blood collection. Multivariable conditional logistic regression models were used to compute odds ratios and 95% confidence intervals to evaluate the association between circulating sex hormones and colon cancer risk. We also conducted a dose-response meta-analysis of prospective studies of circulating estrone and estradiol with colorectal, colon, and rectal cancer risk in postmenopausal women. All statistical tests were 2-sided. Results: In the multivariable model, a nonstatistically significantly positive relationship was found between circulating estrone and colon cancer risk (odds ratio per log2 1-unit increment ¼ 1.17 [95% confidence interval ¼ 1.00 to 1.38]; odds ratioquartile4-quartile1 ¼ 1.33 [95% confidence interval ¼ 0.89 to 1.97], Ptrend ¼ .20). Circulating concentrations of estradiol, free estradiol, testosterone, free testosterone, androstenedione, DHEA, progesterone, and SHBG were not associated with colon cancer risk. In the dose-response meta-analysis, no clear evidence of associations were found between circulating estradiol and estrone concentrations with colorectal, colon, and rectal cancer risk. Conclusion: Our observational and meta-analysis results do not support an association between circulating concentrations of endogenous sex hormones and colon or rectal cancer in postmenopausal women.
UR - https://www.scopus.com/pages/publications/85126288006
U2 - 10.1093/jncics/pkab084
DO - 10.1093/jncics/pkab084
M3 - Article
C2 - 34805742
AN - SCOPUS:85126288006
SN - 2515-5091
VL - 5
JO - JNCI Cancer Spectrum
JF - JNCI Cancer Spectrum
IS - 6
M1 - pkab084
ER -
SDG 3 Good Health and Well-being